Effects of bosutinib on the malignant behavior of thyroid papillary carcinoma B-CPAP cells and its mechanisms

doi:10.12047/j.cjap.6373.2022.133

Abstract

Abstract: Objective: To investigate the effects of bosutinib on the malignant behavior of thyroid papillary carcinoma B-CPAP cells and its possible mechanisms. Methods: Thyroid papillary carcinoma B-CPAP cells were cultured in vitro with a concentration gradient of(1、2、3、4 and 5 μmol/L)bosutinib intervened for 24 hours, DMSO was used as the control group. Five parallel compound holes were set in each group. Cell counting kit (CCK-8 method) method was used to detect cell proliferation. Transwell assay and cell wound healing assay were used to detect cell invasion and migration. TUNEL staining assay and flow cytometry were used to detect cell apoptosis. Western blot was used to detect the expressions of autophagic proteins (Beclin-1, LC3, p62) and signal pathway proteins (SIK2, p-mTOR, mTOR, p-ULK1, ULK1). Results: Compared with the control group, the cell proliferation activity, migration ability and invasion ability were decreased (P＜0.01), while the cell apoptosis rate was increased (P＜0.01) in the bosutinib concentration groups of 2, 3, 4 and 5 μmol/L . In the concentration groups of 4 and 5 μmol/L, the expression of Beclin-1 (P＜0.05), LC3- Ⅱ/LC3- Ⅰ (P＜0.05), SIK2 (P＜0.01) and p-ULK1 (P＜0.01) protein was decreased, while the expression of p62 (P＜ 0.05) and p-mTOR (P＜0.01) protein was increased. Conclusion: Bosutinib may inhibit the autophagy of thyroid papillary carcinoma cells through SIK2-mTOR-ULK1 signaling pathway to inhibit their proliferation, invasion and migration and promote apoptosis, thereby weakening their malignant behavior.

Key words: thyroid papillary carcinoma, Bosutinib, autophagy, malignant behavior, cell culture

CLC Number:

R736.1

XIA Hu-bin, WAN Wen-jun, WANG Yu, ZHANG Yi-fan, CAO Wen-zhuo, LI Shu, WU Chao. Effects of bosutinib on the malignant behavior of thyroid papillary carcinoma B-CPAP cells and its mechanisms[J]. CJAP, 2022, 38(6): 730-734.

References

[1] Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer[J]. Nat Rev Endocrinol, 2020, 16(1): 17-29.
[2] 中华人民共和国国家卫生健康委员会.甲状腺癌诊疗规范(2018年版)[J]. 中华普通外科学文献(电子版), 2019, 13(1): 7-21.
[3] 殷德涛, 韩飏, 张亚原, 等. 多灶性甲状腺乳头状癌的临床病理及颈淋巴结转移特征[J]. 中国普通外科杂志, 2017, 26(5):556-560.
[4] Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy[J]. J Hematol Oncol, 2018, 11(1): 84-98.
[5] Vultur A, Buettner R, Kowolik C, et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells[J]. Mol Cancer Ther, 2008, 7(5): 1185-1194.
[6] Noguchi S, Shibutani S, Fukushima K, et al. Bosutinib, an SRC inhibitor, induces caspase-independent cell death associated with permeabilization of lysosomal membranes in melanoma cells.[J]. Vet Comp Oncol, 2018, 16(1): 69-76.
[7] Maes H, Rubio N, Garg AD et al. Autophagy: shaping the tumor microenvironment and therapeutic response[J]. Trends Mol Med, 2013, 19(7): 428-446.
[8] Nagayama Y, Zhao O . Autophagy and thyroid cancer[J]. J Cancer Metast Treat, 2021, 7(1): 81-96.
[9] Bieerkehazhi S, Chen Z, Zhao Y, et al. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling[J]. Oncotarget, 2017, 8(1): 1469-1480.
[10] Tan DS, Haaland B, Gan J, et al. Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer[J]. Mol Cancer, 13, 1(2014-01-24), 2014, 13(1): 13.
[11] Kim WG, Guigon CJ, Fozzatti L, et al. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer[J]. Clin Cancer Res, 2012, 18(5): 1281-1290.
[12] Kazakova D, Shimamura M, Kurashige T, et al. Re-evaluation of the role of autophagy in thyroid cancer treatment[J]. Endocr J, 2022, 69(7): 847-862.
[13] Katheder NS, Khezri R, O'Farrell F, et al. Microenvironmental autophagy promotes tumour growth[J]. Nature, 2017, 541(7637): 417-420.
[14] Chen F, Chen L, Qin Q, et al. Salt-inducible kinase 2: An oncogenic signal transmitter and potential target for cancer therapy[J]. Front Oncol, 2019, 9(2016): 18-24.
[15] Cao W, Li J, Yang K, et al. An overview of autophagy: Mechanism, regulation and research progress[J]. Bull Cancer, 2021, 108(3): 304-322.
[16] 许乐, 张霞, 吴超, 等. SIK2对心肌缺血/再灌注损伤大鼠能量代谢的影响及其机制[J]. 中国应用生理学杂志, 2022, 38(4): 304-307.
[17] 单尚然, 蒋方, 徐淑梅. β片层阻断肽H102对AD小鼠识别记忆能力和脑内AMPK-mTOR自噬相关通路的影响[J]. 中国应用生理学杂志, 2019, 35(1): 1-4.
[18] Ma L, Manaenko A, Ou YB, et al. Bosutinib attenuates inflammation via inhibiting salt-inducible kinases in experimental model of intracerebral hemorrhage on mice[J]. Stroke, 2017, 48(11): 3108-3116.